3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
2
Esophageal Neoplasms
2
Ovarian Neoplasms
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
Gemcitabine
27
Fluorouracil
25
Oxaliplatin
21
Cisplatin
19
Leucovorin
17
Bevacizumab
15
130-nm albumin-bound paclitaxel
13
Docetaxel
12
Capecitabine
12
Albumin-Bound Paclitaxel
12
Paclitaxel
11
Irinotecan
10
Carboplatin
9
pembrolizumab
7
Radiotherapy
6
Pemetrexed
6
Nivolumab
6
Erlotinib Hydrochloride
6
Cyclophosphamide
6
Trastuzumab
5
Ramucirumab
5
Ipilimumab
4
Everolimus
4
Crizotinib
4
Cetuximab
4
vandetanib
3
trastuzumab deruxtecan
3
sargramostim
3
folfirinox
3
Sorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Adenocarcinoma
×
matuzumab
×
Clear all
NCT00215644
2018-11-02
MATRIX EG
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
72 enrolled
7 charts